Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chimeric TherapeuticsCHMMF -96.67%13 EV-to-EBIT is -0.15 as of Jul. 27, 2026. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 378 Biotechnology companies, Chimeric Therapeutics ranks worse than 264550% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Chimeric Therapeutics's Enterprise Value for the quarter that ended in Dec. 2025 was $2.44 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-12.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Chimeric Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimeric Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's EV-to-EBIT falls into.
Chimeric Therapeutics's current Enterprise Value is $1.87 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-12.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chimeric Therapeutics (CHMMF) has a EV-to-EBIT of -0.15 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Chimeric Therapeutics and its competitors. According to the industry distribution chart, Chimeric Therapeutics ranks #999999 out of 378 companies in the Biotechnology industry.
Is Chimeric Therapeutics' EV-to-EBIT too high?
Chimeric Therapeutics' current EV-to-EBIT is -0.15. Based on the distribution chart, Chimeric Therapeutics ranks #999999 out of 378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #999999 out of 378 companies for EV-to-EBIT. This places Chimeric Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 12.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Chimeric Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chimeric Therapeutics's current EV-to-EBIT is -0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current EV-to-EBIT of -0.15. The current EV-to-EBIT is -0.15. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current EV-to-EBIT is -0.15 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
